Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

Sirturo (bedaquiline) approved for conditional use in European Union to treat MDR-TB in adults

Sirturo

The European Medicines Agency has recently approved Sirturo for conditional use in the European Union. A link to the press release is included.

13 Jun 2013

WHO Issues Interim Guidance on the Use of Bedaquiline to Treat

who-logo

The World Health Organization (WHO) has issued interim guidance on the use of bedaquiline, a new tuberculosis drug, for the treatment of multidrug-resistant tuberculosis (MDR-TB).

Bedaquiline Receives Accelerated Approval from the FDA for MDR-TB Rx

FDA-Logo1

The FDA granted Janssen’s TB drug Bedaquiline accelerated approval for treatment of MDR-TB. A link is provided to the FDA press release and Janssen’s full press release is included.

FDA Advisory Committee recommends Janssen’s Bedaquiline for accelerated approval

FDA-Logo1

Yesterday, Nov. 28th, the FDA Ant-infective Drug Advisory Committee voted to recommend Janssen’s Bedaquiline for accelerated approval for the treatment of MDR tuberculosis. A summary of the proceedings is included.

Launch of the Good Participatory Practice Guidelines for TB Drug Trials

cptr gpp tb

The Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens initiative launches guidelines that will facilitate the involvement of communities and participants in the conduct of TB drug trials.

Updated WHO guidelines on Drug-Resistant TB

who-logo

The WHO issued updated guidelines on the programmatic management of drug-resistant TB on August 4, 2011 online in the European Respiratory Journal.

TB R&D Weekly Update: Promoting Fixed-dose Combos for TB control

the union

In this week’s article, Monedero and Caminero conduct a critical review of research on the use of fixed-dosed combinations (FDCs) for tuberculosis with the conclusion that FDCs should continue to be promoted and recommended. Additional links to TB R&D News are included.

New Report on Drugs for Drug-resistant TB

cover msf union report

The Médecins Sans Frontières and The Union will release on World TB Day a new report entitled “DR-TB drugs under the microscope” outlining drugs currently available to treat drug-resistant tuberculosis (DR-TB) including product information, sources of the drug, quality status, and price.

15 Dec 2010

FDA Streamlines Review for Drug Combinations

fda_D_20100122174936

The FDA issued a draft guidance for the drug industry entitled “Guidance for Industry Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination.” This is exciting news for TB drug development, since there is the potential to reduce the time to develop and obtain approval for new regimens by several years. The FDA is accepting comments from the public until February 14, 2011.